Zetonna Generic Name & Formulations
Mechanism of Action
Zetonna Dosage and Administration
<12yrs: not established.
Zetonna Boxed Warnings
Conduct nasal examination before starting treatment. Discontinue if nasal erosion, ulceration, perforation, or Candida infection occurs. Avoid use in patients with recent nasal ulcers/surgery/trauma until healed. Active or quiescent respiratory tract tuberculosis. Infections (eg, fungal, bacterial, viral, parasitic, or ocular herpes simplex). If exposed to measles or chickenpox, consider immunoglobulin prophylactic therapy. Monitor for acute adrenal insufficiency if prolonged systemic corticosteroid therapy is replaced with topical steroids. Monitor for hypercorticism and HPA axis suppression (if occur discontinue gradually) and other nasal cavity changes. Monitor for vision changes or in those with a history of increased intraocular pressure, glaucoma or cataracts. Monitor for growth suppression in children. Avoid spraying in eyes or directly onto the nasal septum. Pregnancy. Nursing mothers.
Ciclesonide and des-ciclesonide have negligible oral bioavailability (both <1%) due to low GI absorption and high first-pass metabolism.
Following IV administration of 800 mcg of ciclesonide, the volumes of distribution of ciclesonide and des-ciclesonide were ~2.9 L/kg and 12.1 L/kg, respectively. The percentage of ciclesonide and des-ciclesonide bound to human plasma proteins averaged ≥99% each, with ≤1% of unbound drug detected in the systemic circulation. Des-ciclesonide is not significantly bound to human transcortin.
Fecal (66%), renal (≤20%).
Zetonna Adverse Reactions
Zetonna Clinical Trials
Zetonna Patient Counseling